The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.
Boehncke
W-H
WH
Ludwig
R J
RJ
Zollner
T M
TM
Ochsendorf
F
F
Kaufmann
R
R
Gibbs
B F
BF
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002908:Chronic Disease; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013450:Sulfones; D014581:Urticaria / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib